R&D News | pharmaphorum

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Alnylam showcases long-acting amyloid drug at AAIC

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially

News

Lilly bulks up in obesity with $1.93bn Versanis buy

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1

News

First Wave faces choppy waters with cystic fibrosis drug

First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f

News

Apogee Therapeutics upsizes its IPO to $300m

In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill

News

Roche eyeing $7bn deal to buy Roivant drug; report

Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco

Donanemab data an “important advance” in Alzheimer’s

Alnylam showcases long-acting amyloid drug at AAIC

Lilly bulks up in obesity with $1.93bn Versanis buy

First Wave faces choppy waters with cystic fibrosis drug

Apogee Therapeutics upsizes its IPO to $300m

Roche eyeing $7bn deal to buy Roivant drug; report

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks